|Bid||1.1400 x 1200|
|Ask||1.1900 x 3100|
|Day's Range||1.1000 - 1.1900|
|52 Week Range||0.3710 - 1.9380|
|Beta (5Y Monthly)||2.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
By John Vandermosten, CFA NASDAQ:AZRX On July 20, 2020, AzurRx (NASDAQ: AZRX) announced the closing of $15.2 million in a private placement and repayment of $6.9 million in convertible notes. The proceeds in excess of the liability repayment will be used to advance the two Phase II clinical trials of MS1819 in patients with cystic fibrosis. The company issued 2,912 shares of Series B Convertible
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of AzurRx BioPharma, Inc. (NASDAQ: AZRX).